Publications by authors named "Claudia Cellini"

Claim this Profile
I
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.
Emanuele Zucca, Luca Ceriani, Giovannino Ciccone, Alice Di Rocco, Maria Cristina Pirosa, Claudia Cellini

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicians' Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy.
Lorenzo Cani, Maria Teresa Petrucci, Katia Mancuso, Renato Zambello, Laura Paris, Claudia Cellini

Clin Lymphoma Myeloma Leuk· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial.
Sara Bringhen, Lorenzo Cani, Elisabetta Antonioli, Daniele Derudas, Francesca Fazio, Claudia Cellini

Lancet Haematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.
Maurizio Martelli, Luca Ceriani, Giovannino Ciccone, Umberto Ricardi, Iryna Kriachok, Claudia Cellini

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Mattia D'Agostino, Giuseppe Bertuglia, Delia Rota-Scalabrini, Angelo Belotti, Sonia Morè, Claudia Cellini

Blood· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Roberto Mina, Pellegrino Musto, Delia Rota-Scalabrini, Laura Paris, Barbara Gamberi, Claudia Cellini

Lancet Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.
Roberto Mina, Antonietta Pia Falcone, Sara Bringhen, Anna Marina Liberati, Norbert Pescosta, Claudia Cellini

Blood Cancer J· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.
Edward A Stadtmauer, Keith M Sullivan, Mohamed El Idrissi, Bruno Salaun, Aránzazu Alonso Alonso, Claudia Cellini

Hum Vaccin Immunother· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Alessandra Larocca, Francesca Bonello, Gianluca Gaidano, Mattia D'Agostino, Massimo Offidani, Claudia Cellini

Blood· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study.
Beatrice Anna Zannetti, Francesco Saraceni, Claudia Cellini, Elisabetta Fabbri, Federica Monaco

Transplant Cell Ther· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial.
Andrés J M Ferreri, Jeanette K Doorduijn, Alessandro Re, Maria Giuseppina Cabras, Jeffery Smith, Claudia Cellini

Lancet Haematol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Paola Tacchetti, Lucia Pantani, Francesca Patriarca, Maria Teresa Petrucci, Elena Zamagni, Claudia Cellini

Lancet Haematol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Sara Bringhen, Mattia D'Agostino, Laura Paris, Stelvio Ballanti, Norbert Pescosta, Claudia Cellini

Haematologica· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study.
Roberto Mina, Angelo Belotti, Maria Teresa Petrucci, Renato Zambello, Andrea Capra, Claudia Cellini

Blood Cancer J· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Beatrice Anna Zannetti, Paola Tacchetti, Lucia Pantani, Barbara Gamberi, Patrizia Tosi, Claudia Cellini

Ann Hematol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach.
Francesco Lanza, Francesco Saraceni, Annalisa Pezzi, Massimo Martino, Alberto Bosi, Claudia Cellini

Am J Hematol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
Francesco Zaja, Simone Ferrero, Caterina Stelitano, Angela Ferrari, Flavia Salvi, Claudia Cellini

Haematologica· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure.
Patrizia Tosi, Barbara Gamberi, Barbara Castagnari, Anna Lia Molinari, Paolo Savini, Claudia Cellini

Mediterr J Hematol Infect Dis· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Antonio Palumbo, Michele Cavo, Sara Bringhen, Elena Zamagni, Alessandra Romano, Claudia Cellini

J Clin Oncol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Michele Cavo, Paola Tacchetti, Francesca Patriarca, Maria Teresa Petrucci, Lucia Pantani, Claudia Cellini

Lancet· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
Antonio Curti, Patrizia Tosi, Patrizia Comoli, Carolina Terragna, Elisa Ferri, Claudia Cellini

Br J Haematol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.
Michele Cavo, Patrizia Tosi, Elena Zamagni, Claudia Cellini, Paola Tacchetti

J Clin Oncol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
Patrizia Tosi, Elena Zamagni, Delia Cangini, Paola Tacchetti, Francesco Di Raimondo, Claudia Cellini

Blood· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Patrizia Tosi, Elena Zamagni, Claudia Cellini, Raffaele Parente, Delia Cangini

Eur J Haematol· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission.
Michele Cavo, Carolina Terragna, Matteo Renzulli, Elena Zamagni, Patrizia Tosi, Claudia Cellini

J Clin Oncol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis